Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Macimorelin - AEterna Zentaris

Drug Profile

Macimorelin - AEterna Zentaris

Alternative Names: AEZS-130; ARD-07; D-87575; EP-01572; EP-1572; Ghryvelin; JMARD-07; JMV-1843; Macimorelin acetate; Macrilen; Solorel

Latest Information Update: 18 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AEterna Zentaris Inc
  • Developer AEterna Zentaris Inc; Consilient Health; Novo Nordisk; University of Queensland
  • Class Amides; Carboxylic acids; Diagnostic agents; Indoles; Oligopeptides; Small molecules
  • Mechanism of Action Ghrelin receptor agonists; Ghrelin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Somatotropin deficiency
  • New Molecular Entity Yes
  • Available For Licensing Yes - Somatotropin deficiency

Highest Development Phases

  • Marketed Somatotropin deficiency
  • Phase II Cachexia
  • Preclinical Amyotrophic lateral sclerosis

Most Recent Events

  • 13 Jun 2024 AEterna Zentaris completes a phase III DETECT trial for Somatotropin deficiency (Diagnosis, In children, In adolescents) in USA, Armenia, Georgia, Poland, Italy, Slovenia, Germany, Romania, Serbia, Slokavia and Turkey (PO) (NCT04786873) (EudraCT2018-001989-42)
  • 27 Mar 2024 Phase-III clinical trials in Somatotropin deficiency (Diagnosis, In children, In adolescents) in Armenia, Turkey (PO) prior to March 2024 (NCT04786873)
  • 27 Mar 2024 AEterna Zentaris completes enrolment in the phase III DETECT trial for Somatotropin deficiency in Georgia, Poland, Italy, Slovenia, Germany, Romania, Serbia, Slokavia, USA (PO) (NCT04786873) (EudraCT2018-001989-42)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top